Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Analysis Sustains TAS-102 Survival Benefit in Gastric Cancer

January 19th 2019

Overall survival in metastatic gastric/gastroesophageal junction cancer improved significantly in patients who received the combination therapy TAS-102, irrespective of prior gastrectomy.

Dr. Shroff Discusses Molecular Profiling in Cholangiocarcinoma

January 19th 2019

Rachna T. Shroff, MD, MS, discusses the importance of molecular profiling upon diagnosis in patients with cholangiocarcinoma.

Dr. Noel on the Impact of SM-88 in Pancreatic Cancer

January 19th 2019

Marcus Noel, MD, discusses the data of SM-88 and how it will impact the treatment of patients with metastatic pancreatic cancer.

Ramucirumab/Nivolumab Combo Shows Potential in Advanced Gastric Cancer

January 18th 2019

The combination of nivolumab and ramucirumab has activity in patients with previously treated advanced gastric adenocarcinoma, investigators reported at the 2019 Gastrointestinal Cancers Symposium.

Dr. Ocean on the Toxicities With SM-88 in Metastatic Pancreatic Cancer

January 18th 2019

Allyson J. Ocean, MD, discusses her experiences with SM-88 in patients with metastatic pancreatic cancer.

Pembrolizumab/Trastuzumab Induction Highly Active in HER2+ Gastric, GEJ Cancer

January 18th 2019

Two-thirds of patients with untreated metastatic HER2-positive esophagogastric adenocarcinoma remained free of disease progression at 6 months with a combination of pembrolizumab, trastuzumab, and chemotherapy.

Pembrolizumab Shows OS Benefit in PD-L1+ Esophageal Cancer

January 18th 2019

Pembrolizumab was found to reduce the risk of death by 31% in patients with PD-L1–positive advanced or metastatic esophageal or esophageal junction carcinoma who progressed on standard therapy.

Nivolumab Alone or With Ipilimumab Provides Durable Benefit in MSI-H/dMMR mCRC

January 24th 2018

Data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.

Napabucasin Plus Pembrolizumab Shows Early Promise in mCRC

January 23rd 2018

Combining the investigational oral cancer stem cell pathway inhibitor napabucasin with the PD-1 inhibitor pembrolizumab showed a signal of efficacy in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer.

Dr. Chau on the Tolerability of Ramucirumab Plus Pembrolizumab in Gastric/GEJ Cancer

January 23rd 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the tolerability of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

Dr. Bekaii-Saab Discusses QoL With Regorafenib Dose Escalation in mCRC

January 23rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the quality of life findings for a dose-escalation study of regorafenib (Stivarga) in metastatic colorectal cancer.

Pembrolizumab Promising After Sorafenib in Advanced HCC

January 21st 2018

Treatment with the PD-1 inhibitor pembrolizumab elicited promising progression-free survival and overall survival results in patients with advanced hepatocellular carcinoma who received previous treatment with sorafenib.

Cetuximab Plus Pembrolizumab Well Tolerated in RAS Wild-Type mCRC

January 21st 2018

The combination of cetuximab and pembrolizumab was found to be well tolerated in patients with RAS wild-type metastatic colorectal cancer.

Lenvatinib Plus Pembrolizumab or Nivolumab Active in Intrahepatic Cholangiocarcinoma

January 21st 2018

Combining lenvatinib (Lenvima) with PD-1 inhibitors had promising efficacy in patients with advanced intrahepatic cholangiocarcinoma, according to preliminary data from a single-center study.

Regorafenib Before Cetuximab Improves Survival in mCRC

January 21st 2018

Sequencing regorafenib before cetuximab showed superior overall survival compared with the reverse sequence in patients with metastatic colorectal cancer following failure of standard chemotherapy.

Dr. Overman on Updated Findings With Nivolumab in Metastatic CRC

January 21st 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the updated findings from CheckMate-142 in metastatic colorectal cancer during the 2018 Gastrointestinal Cancers Symposium.

Dr. Abou-Alfa Discusses Results of the CELESTIAL Trial in Advanced HCC

January 21st 2018

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the CELESTIAL trial in advanced hepatocellular carcinoma during the 2018 Gastrointestinal Cancers Symposium.

Nab-Paclitaxel/Gemcitabine Effective for Locally Advanced Pancreatic Cancer

January 20th 2018

Induction treatment with nab-paclitaxel plus gemcitabine demonstrated a time to treatment failure of 8.8 months for patients with newly diagnosed locally advanced pancreatic cancer.

Regorafenib Dose Escalation Superior in Metastatic CRC

January 20th 2018

Tanios Bekaii-Saab, MD, discusses the results and significance of the ReDOS study in metastatic colorectal cancer, as well as shared some insight on the Reverce trial.

Dr. Pishvaian Discusses Results of Entrectinib in Metastatic Pancreas Cancer

January 20th 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study of entrectinib in patients with pancreas cancer.